Immunocompatible amniotic membrane products
AssigneeOsiris Therapeutics, Inc.
InventorsSamson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
Life of this patent
Estimating the term…
Abstract
Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.
Claims20
A cryopreserved amniotic membrane comprising viable cells native to the amniotic membrane;
- wherein the cryopreserved amniotic membrane is immunocompatible;
- wherein at least 70% of the cells are viable;
- wherein the viable cells comprise two or more cell types consisting of MSCs, fibroblasts, and epithelial cells;
- wherein the cryopreserved amniotic membrane comprises less than about 1% of CD14+ macrophages.
A previously cryopreserved membrane comprising an amniotic membrane, wherein the previously cryopreserved amniotic membrane comprises:
- a) viable cells, wherein said viable cells are native to the amniotic membrane before cryopreservation and greater than 70% of said cells are viable, wherein the viable cells comprise two or more cell types consisting of MSCs, fibroblasts, and epithelial cells;
- b) one or more therapeutic factors that are native to the amniotic membrane;
- c) extracellular matrix that is native to the amniotic membrane;
- and
- d) less than about 1% of CD14+ macrophages.
Dependencies are inferred from the claim text.